{
  "attach_pages": "7",
  "attach_size": "799",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201804271132171472_1.pdf?1547716668000.pdf",
  "company_code": "80114781",
  "eitime": "2018-04-27 15:24:20",
  "extend": {},
  "info_code": "AP201804271132171472",
  "language": "0",
  "notice_date": "2018-04-27 00:00:00",
  "notice_title": "2018年一季报点评：业绩稳健符合预期，PD-1单抗&瑞马唑仑进入优先审批值得期待",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "张金洋,胡偌碧",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "恒瑞医药",
      "short_name_ch": "恒瑞医药",
      "short_name_cht": "恒瑞醫藥",
      "short_name_en": "HENGRUI PHARMA",
      "stock": "600276"
    }
  ],
  "short_name": "恒瑞医药",
  "source_sample_name": "东兴证券",
  "star": "1"
}